



GASTRORETENTIVE DRUG DELIVERY SYSTEM

M Sharath Chandra Goud and V P Pandey

Department of Pharmacy, Annamalai University, Annamalai Nagar, Chidambaram, Tamilnadu 608002

*Corresponding Author Email: goudsharathchandra@gmail.com

ABSTRACT

Oral sustained drug release and specific site drug delivery system in pharmaceutical field to achieve improved therapeutic advantage. Drug absorption in GIT varies and increased gastric retention time of the dosage form extends the time of drug absorption. It is one of the novel drug delivery system to prolong gastric residence time. Thereby implementing site specific drug release in the stomach for local and systemic effect. It is very useful for the drugs which having narrow absorption Rate. Various forms of gastro retentive drug delivery system, such as floating and non-floating. This article can give an account on merits, demerits and evaluation parameters of gastro retentive system.

KEY WORDS

Gastro retentive drug delivery system, non-floating system, floating system, evaluation parameters

INTRODUCTION

Advancement in drug delivery, oral route is the most common route to the systemic circulation due to easiest way of administration, low cost of drug, patient compliance and flexibility in formulation. About 90% of all drugs used are administered by oral route. Though the drugs are administered orally, solid oral dosage forms is the most common class of products. Tablets are the most common type of solid dosage form in use which is classified based on the drug release pattern, i.e. immediate release and modified release. The immediate release tablets have many drawbacks including non-site specific drug release. However, many drugs are absorbed from specific sites and they require release at that site only for better absorption. Drug absorption in the GIT is a highly variable process and it is depending on the factors like gastric emptying process, gastrointestinal transit time of dosage forms, drug release from the dosage form, and site of absorption of drugs. Drugs that are absorbed easily from the GIT and have short half-lives are eliminated quickly from the systemic circulation. Frequent dose is required to achieve suitable therapeutic activity.

Gastro retentive drug delivery is one of those approaches to prolong gastric residence time, thereby targeting site specific drug release in the stomach for local or systemic effects. These dosage forms can remain in the gastric region for long periods and hence significantly prolong the gastric retention time of the drugs. It will release the drug in stomach in a controlled manner, so that the drug could be supplied continuously to absorption site in GIT i.e. stomach.

MERITS OF GASTRORETENTIVE DRUG DELIVERY SYSTEM (GRDDS):

The GRDDS has the following advantages:

- Increased bioavailability: The bioavailability of the drugs having absorption in the upper part of the GIT like riboflavin, levodopa has tremendously been increased than that of the normal dosage forms.
- Sustained drug release and reduced frequency of dosing. This improves patient compliance.
- Targeted delivery of the drug at the upper part of the GIT making it suitable for the local treatment of the disease of the region e.g.; antacids, anti-ulcer drugs, antibacterial for H. pylori infection.

- Suitable for the drugs which have pH dependent absorption from stomach eg., Furosemide, Captopril, Diazepam, Verapamil, Cefpodoxime proxetil.
- Suitable for the drugs which degrade in the intestine or column e.g., Ranitidine hydrochloride.
- Drug level fluctuation is not observed and maintains the optimal therapeutic plasma and tissue concentrations over prolonged time period. This avoids sub-therapeutics as well as toxic concentration and minimizes the risk of failure of the medical treatment and undesirable side effects.

LIMITATIONS OF GRDDS:

- It is not suitable for the drugs which are not stable in acidic environment.
- It is not suitable for the drugs which are absorbed better in the lower part of GIT.
- Difficulty to attain the desired outcome and problem of the dose dumping.
- Gastric retention is influenced by many factors like gastric motility, pH and presence of food. Hence, the dosage form must be able to withstand the grinding and churning force of peristaltic wave of stomach.
- Poor in vitro and in vivo correlation.
- Higher cost of formulation.
- Retrieval of drug is difficult in case of toxicity, poisoning or hypersensitivity reaction.

Other drawbacks associated with specific types of GRDDS are given the table below

Technology	Drawbacks
High density system	Very difficult to incorporate large number of drugs. No such systems are available in the market till date
Floating system	Floating highly depends on the fed state of the stomach and higher level of fluid is required in gastric region
Expandable system	Chocking problem; storage problem due to hydrolysable and biodegradable polymers; difficult to manufacture and not economical
Mucoadhesive system	Can be detached from gastric mucosa due to rapid turnover of mucus and peristaltic wave of stomach. It may also attach to the mucus of oesophagus
Magnetic system	Problem with patient compliance

FACTORS AFFECTING THE GRDDS:

Since many factors affects the gastric emptying process, which may seriously affect the release of a drug and its absorption, it is desirable to develop a drug delivery system that exhibits an extended gastric residence and a drug release profile independent of patient related variables.

The factors that affect the gastric emptying and hence the gastric retention of the drugs includes:

- Fasting or fed state of the stomach: During the fasting state an inter-digestive series of electrical events take place, which cycle both through stomach and intestine every 2 to 3 hours. In the fed state, this cycle is delayed and hence the gastric emptying rate is slowed.
- Size, Density and shape of the dosage form.
- Intake of food along with drugs: the nature of the food, calorie content and its frequency of intake

have considerable effect on the retention of drugs in stomach.

- Concomitant administration of drugs like anticholinergic agents e.g., atropine, propantheline and opiates delay the gastric emptying while the prokinetic agents like metoclopramide and cisapride enhance the gastric emptying process.
- Biological factors such as gender, posture, age, sleep, body mass index, physical activity and disease states e.g. diabetes and Crohn's disease.

DIFFERENT APPROACHES OF THE GRDDS

Different approaches have been pursued to increase the retention of oral dosage forms in the stomach. Some are formulated as single component whereas others are formulated as multi-component dosage forms. GRDDS can be broadly categorized into floating and non-floating system.

A. Non-floating system: These GDDS do not float in the stomach however they remain retained there by different mechanisms. Non-floating system is further divided into:

- a. High density (sinking) drug delivery system
- b. Bioadhesive or mucoadhesive system
- c. Magnetic system
- d. Unfoldable system

B. Floating drug delivery system (FDDS): In contrast to the high-density drug delivery system, floating systems have density less than the gastric content so the system remain in the stomach for a prolonged period of time without affecting the gastric contents. Floating drug delivery systems are also known as low density system. Figure 1 shows the mechanism of floating of this system




Figure 1: The mechanism of floating system

Floating drug delivery system can be divided into:

- a. Effervescent system
- b. Noneffervescent system
 - i. Hydrodynamically balanced system
 - ii. Microballoons or hollow microspheres
 - iii. Alginate beads
 - iv. Microporous compartment

A. Non-floating system

a. High Density (Sinking) Drug Delivery System

In this approach formulations are prepared by coating drug on a heavy core or mixed with inert materials such as iron powder, barium sulfate, zinc oxide and titanium oxide so that the density of the formulation exceeds the density of the normal gastric content. These materials increase the density up to 1.5-2.4 gm/cm³. Depending on density, the GI transit time of pellets can be extended from an average of 5.8 to 25 hours. But effectiveness of this system in human beings was not observed [30] and no formulation has been marketed.

b. Bioadhesive or mucoadhesive system

The gastric retention time is extended by adhering the bioadhesive system to gastric mucosa membrane. The adherence of the delivery system to the gastric wall increases residence time thereby improving bioavailability. The chemicals used for the mucoadhesion purpose include polycarbophil,

carbopol, lectin, chitosan, carboxy methyl cellulose, gliadin etc. Novel adhesive material derived from fimbriae of bacteria or its synthetic analogues have also been tried for the attachment to the gut.

However, gastric mucoadhesive force does not tend to be strong enough to resist the propulsion force of stomach wall. The continuous production of mucus and dilution of the gastric content is another limitation for such type of system. Many investigators have tried out a synergistic approach between floating and bioadhesion system.

c. Magnetic system

In this system, the dosage form contains a small magnet and another magnet is placed on the abdomen over the position of the stomach. The external magnet should be placed with a degree of precision which may decrease the patient compliance.

d. Unfoldable system

The drug delivery system unfolds and increases in size and it remains lodged at sphincter avoiding its exit from the stomach. For this the system, should be small enough to be swallowed but unfold itself when it comes in contact with gastric fluid, and after a certain period of time its size should become small so that it will be easily evacuated. The unfoldable systems are made up of different biodegradable polymers.

B. Floating Drug Delivery System

a. Effervescent System

This system consists of the swellable polymers like chitosan and effervescent substance like sodium bicarbonate, disodium glycine carbonate, cytoglycine, citric acid and tartaric acid. When the system comes in contact with gastric fluid, it releases carbon dioxide causing the formulation to float in the stomach. The optimal ratio of citric acid and sodium bicarbonate for gas generation is reported to be 0.76:1. This system is further divided as single unit matrix tablets or multiple unit pills. Single unit matrix tablet may be single or multilayer type. Floating system with ion exchange resins has also been reported. Effervescent system and drug release from such system.

b. Non-effervescent system

In this system, gel forming or highly swellable cellulose type hydrocolloids, polysaccharides, and matrix forming polymers such as polycarbonate, polyacrylate, polymethacrylate and polystyrene are used. After oral administration, this dosage form swells in contact with gastric fluids and attains a bulk density of less than 1. The air entrapped within the swollen matrix imparts buoyancy to the dosage form. The so formed swollen gel-like structure acts as a reservoir and allows sustained release of drug through the gelatinous mass. Superporous hydrogels are an excellent example working in this approach. The dosage form swells significantly to several times of original volume upon contact with gastric fluid, the gastric contraction pushes the dosage form to the pylorus but due to larger size of the dosage form, the contractions slip over the surface of the system, due to which the dosage form pushes back into the stomach.

Non-effervescent system can be further divided in to: hydrodynamically balanced system, microballoons, alginate beads, and microporous compartment.

i. Hydrodynamically balanced system: The hydrodynamically balanced system (HBS) was first designed by Sheth and Tossounian. HBS contains drug with gel-forming hydrocolloids meant to remain buoyant on the stomach content. This system contains one or more gel forming cellulose type hydrocolloid e.g., hydroxypropyl methyl cellulose, ethyl cellulose, hydroxypropyl cellulose, agar, carrageen or alginic acid. It also contains matrix forming polymers such as polycarbophil, polyacrylate and polystyrene. When such system comes in contact with gastric fluid, the

hydrocolloid in the system hydrates and forms a colloid gel barrier around its surface.

ii. Microballoons or hollow microspheres: Hollow microspheres (microballoons), loaded with drug in their outer polymer shells, are prepared by emulsion-solvent diffusion method. The steps involved in this method are summarized in figure 9. The ethanol: dichloromethane solution (1:1) and an acrylic polymer are poured into an agitated aqueous solution of polyvinyl alcohol at 40°C. The gas phase generated in the dispersed polymer droplet by the evaporation of dichloromethane form an internal cavity in the microsphere of the polymer with the drug. The microballoons float continuously over the surface of acidic dissolution media containing surfactant for more than 12 hours.

iii. Alginate beads: Freeze dried calcium alginates have been used to develop multi-unit floating dosage forms. By dropping sodium alginate solution into aqueous solution of calcium chloride spherical beads of about 2.5 mm diameter can be prepared. These beads are separated and air dried. This results in the formation of aporous system which remains buoyant in the stomach.

iv. Microporous compartment: In this system, drug reservoir is encapsulated inside a microporous compartment having pores along its top and bottom walls. The floatation chamber containing entrapped air causes the delivery system to float over the gastric content. Gastric fluid enters through the aperture, dissolves the drug and carries the dissolved drug in stomach and proximal part of the small intestine for absorption.

PROBABLE CANDIDATES FOR GRDDS:

Following are the probable candidates, but not limited to, for gastro retentive drug delivery system:

- Drugs required to exert local therapeutic action in the stomach: antacids, anti-H.pylori agents, misoprostol [24]
- Drugs that have narrow absorption window in stomach or upper parts of the small intestine, e.g., furosemide [38], riboflavine-5-phosphate [39], metformin hydrochloride [40], ciprofloxacin [41], alfuzosin hydrochloride [42], ofloxacin [43], norfloxacin [44], domperidone [45] etc.
- Drugs that disturb normal colonic bacteria, e.g., amoxicillin tirhydrate [46]

- Drugs unstable in the lower part of GIT, e.g., captopril [47]
- Drugs insoluble in intestinal fluids, e.g., quinidine, diazepam [48]
- Drugs that degrade in the colon, e.g., ranitidine hydrochloride [49], metronidazole [50]

MARKETED PRODUCTS OF GRDDS:

Following are some gastro-retentive products which are available in market:

Brand name	Active ingredients
Cifran OD [®]	Ciprofloxacin
Madopar [®]	LDopa and Benserazide
Valrelease [®]	Diazepam
Topalkan [®]	Aluminium-magnesium antacid Almagate
FlatCoat [®]	Aluminium-magnesium antacid
Liquid Gavision [®]	Aluminium hydroxide
Convion [®]	Ferrous sulfate
Cytotec [®]	Misoprostal

EVALUATION PARAMETERS OF GRDDS:

Evaluation parameters of GRDDS generally include:

1. Drug-excipient interaction

It is done by using FTIR and HPLC. Appearance of a new peak and/or disappearance of original drug or excipient peaks indicate the drug excipient interaction.

2. Floating lag time

It is the time taken to emerge tablet onto the surface after it is kept in to the dissolution medium. It is measured in minutes or seconds.

3. In vitro drug release and duration of floating

It is determined by using USP II apparatus (paddle) stirring at a speed of 50 or 100 rpm at 37±2°C in simulated gastric fluid of pH 1.2. Aliquots of the samples are collected and analyzed for the drug content. The time for which the drug remains floating on the surface of the medium is the duration of the floating time.

4. In vivo evaluation of gastric retention

Analysis of the position of the dosage form in the GIT involves an imaging technique such as γ-scintigraphy and X-ray.

- In γ-scintigraphy, a small amount of stable isotope is compounded in the dosage forms during its preparation. The inclusion of a γ-emitting radio-nuclide in a formulation allows indirect external observation using a γ-camera or scinti scanner.

- For x-ray, barium sulfate is used as a contrast medium. It helps to locate dosage form in the GIT by which one can predict and correlate the gastric emptying time and the passage of dosage form.

In addition, gastroscopy and ultrasonography studies can be included in the in vivo evaluation of GRDDS. Gastroscopy comprises of per-oral endoscopy, used with a fiberoptic and video systems. Ultrasonography is not routinely used in the evaluation of GRDDS. In vivo plasma profile can also be obtained by performing the study in suitable animal model.

5. Water uptake study

It is done by immersing the dosage form in simulated gastric fluid at 37°C and determining the dimensional changes, such as diameter and thickness, at regular interval of time. After the stipulated time the swollen tablets are weighed and water uptake is measured in the terms of percentage weight gain, as given:

$$WU = \frac{(W_t - W_o) \times 100}{W_o}$$

in which, W_t and W_o are the weight of the tablet after time t and initially, respectively.

The tablets are also evaluated for hardness, friability, weight variation etc. which are applicable for conventional instant release tablets. For the multiple unit dosage forms like microsphere following tests are also essential apart from the above tests:

- Morphological and dimensional analysis: It is done with the aid of scanning electron microscopy and optical microscope.
- Percentage yield of microsphere.

- Entrapment efficiency: The drug is extracted by suitable method and analyzed to find out the amount of drug present.

CONCLUSION

Gastro retentive drug delivery technologies have been extensively explored in recent years. GRDDS has the potential to enable many drugs to provide less frequent dosing and remains undoubtedly beneficial for the drugs having NAW in the stomach and/or upper part of the intestine. However, there are many obstacles that need to be overcome to obtain the maximum benefit of the system. Despite this many researchers are working towards the best utilization of this technique, some with success and others with failure due to unpredictability of the human GIT. Thus, to formulate a successful GRDDS, it is necessary to take into consideration the physiological event in the GIT, selection of correct combinations of drugs and excipients and design appropriate formulation strategies.

REFERENCES

- [1] Lachman L, Liberman HA & Kanig JL, *The theory and practice of industrial pharmacy*, Lea &Febiger, Philadelphia, (1986) 293, ISBN 0-8121-0977-5.
- [2] Aulton M, *Aulton's Pharmaceutics: The design and manufacture of medicines*, Churchill Livingstone, London, (2007) 397, ISBN 0-443-055173.
- [3] Niranjanbhai BD, Mahendrakumar VN, Surendran CS, HSV &UMU, Advances in GRDDS: Raft forming system a review, *Journal of Drug Delivery & Therapeutics*, 2 (2012) 123.
- [4] Strebeul A, Siepmann J & Bodmeier R, Gastro retentive drug delivery system, *Expert Opin Drug Deliv*, 3 (2006) 217.
- [5] Bardonnnet PL, Faivre V, Pugh WJ, Piffaretti JC & Falson F, Gastroretentive dosage forms: overview and special case of *Helicobacter pylori*, *J Control Release*, 111 (2006) 1. [6] Pawar VK, Kansal S, Garg G, Awasthi R, Singodia D & Kulkarni GT, Gastroretentive dosage forms: A review with special emphasis on floating drug delivery systems, *Drug Delivery*, 18 (2011) 97.
- [7] Nayak AK, Maji R & Das B, Gastroretentive drug delivery system: A review, *Asian Journal of Pharmaceutical and clinical research*, 3 (2010) 1.
- [8] Vyas SP & Kar RK, *Controlled drug delivery: Concept and advances*, CBS Publication, Noida (2008).
- [9] Garg S & Sharma S, Gastroretentive Drug Delivery System, *Business Briefing: Pharmatech*, (2003) 160.
- [10] Hoffman A, Stepensky D, Lavy E, Eyal S, Klausner E & Friedman M, Pharmacokinetic and pharmacodynamic aspects of gastroretentive dosage forms, *Int. J. Pharm*, 277 (2004) 141.
- [11] Klausner EA, Lavy E, Barta M, Friedman M, Cserepes E, Barta M, Friedman M & Hoffman A, Novel gastroretentive dosage forms: evaluations of gastro retentivity and its effect on levodopa absorption in humans, *Pharm. Res.*, 20 (2003) 1466.
- [12] Whitehead L, Collett JH & Fell JT, Amoxycillin release from a floating dosage form based on alginates, *Int. J. Pharm.*, 210 (2000) 45.
- [13] Ozdemir N, Ordu S & Ozkan Y, Studies of floating dosage forms of furosemide: in vitro and in vivo evaluations of bilayer tablet formulations, *Drug Dev. Ind. Pharm.*, 26 (2000) 857.
- [14] Robles LV, Martinez I & Barreda TQ, Sustained delivery of captopril from floating matrix tablets, *Int. J. Pharm.*, 362 (2008) 37.
- [15] Soppimath KS, Kulkarni AR & Aminabhavi TM, Development of hollow microspheres as floating controlled release systems for cardiovascular drugs: preparation and release characteristics, *Drug Dev. Ind. Pharm.* 27 (2001) 507.
- [16] Basit A, Colonic metabolism of ranitidine: implications for its delivery and absorption, *Int. J. Pharm.* 227 (2001) 157.
- [17] Pawar VK, Kansal S, Asthana S & Chourasia MK, Industrial Perspective of Gastroretentive Drug Delivery System: Physiochemical, Biopharmaceutical, Technological and regulatory considerations, *Expert opinion on drug delivery*, 9(2012) 551.
- [18] Whitehead L, Fell JT, Collett JH, Sharma HL & Smith AM, Floating dosage forms: an in vivo study demonstrating prolonged gastric retention, *J. Control. Rel.*, 55 (1998) 3.
- [19] Deshpande AA, Rhodes CT, Shah NH & Mallick AW, Controlled-Release Drug Delivery Systems for Prolonged Gastric Residence: An Overview, *Drug Dev. Ind. Pharm.*, 22 (1996), 531.
- [20] Coupe AJ, Davis SS, Evans DF & Wilding IR, The effect of sleep on the gastrointestinal transit of pharmaceutical dosage forms, *Int. J. Pharm.*, 78 (1992) 69.
- [21] Khosla R & Davis SS, The effect of tablet size on the gastric emptying of non-disintegrating tablets, *Int. J. Pharm.*, 62 (1990), R9-R11.
- [22] Timmermans J & Moes AJ, Factors controlling the buoyancy and gastric retention capabilities of floating matrix capsules: new data for reconsidering the controversy, *J. Pharm. Sci.* 83 (1994) 18.
- [23] Abrahamsson B, Alpsten M, Hugosson M, Jonsson UE, Sundgren M, Svenheden A & Tölli J, Absorption, Gastrointestinal Transit, and Tablet Erosion of Felodipine

- Extended Release (ER) Tablets, *Pharm. Res.*, 10 (1993) 709.
- [24] Oth M, Franz M, Timmermans J & Moes AJ, The bilayer floating capsule: A stomach-directed drug delivery system for misoprostol, *Pharm Res.*, 9 (1992) 298.
- [25] Hocking MP, Brunson ME & Vogel SB, Effect of various prokinetic agents on post Roux-en-Y gastric emptying, *Digestive Diseases and Sciences*, 33 (1988), 1282.
- [26] Kaus LC, Fell JT, Sharma H & Taylor DC, Gastric emptying and intestinal transit of non-disintegrating capsules--the influence of metoclopramide, *Int. J. Pharm.*, 22 (1984) 99.
- [27] Bennett CE, Hardy JG & Wilson CG, The influence of posture on the gastric emptying of antacids, *Int. J. Pharm.*, 21 (1984), 341.
- [28] Hermansson G & Sivertsson R, Gender-related differences in gastric emptying rate of solid meals, *Digestive Diseases and Sciences*, 41 (1996), 1994.
- [29] Vyas SP & Khar RK, *Gastro retentive systems*, In: Controlled drug delivery, Vallabh Prakashan, Delhi, (2006) 197.
- [30] Moes AJ, Gastric retention system for oral drug delivery. *Business briefing: Pharmatech*, (2003) 157.
- [31] Misra SK, Gastrointestinal targeting drug delivery system: A Review. *Journal of Pharmacy Research*, 4 (2011) 2751.
- [32] Rao BP, Kottan NA, Snehith VH & Ramesh C, Development of gastroretentive drug delivery system of cephalexin by using factorial design, *ARS Pharmaceutica*, 50 (2009) 8.
- [33] Arora S, Ali J, Khar RK & Baboota S. Floating drug delivery systems: A review, *AAPS Pharm Sci Tech*, 6 (2005) 372.
- [34] Chen J, Blevins WE, Park H & Park K, Gastric retention properties of superporous hydrogel composites, *J. Control. Release.*, 64 (2000) 39.
- [35] Sheth PR & Tossounian J, The Hydrodynamically Balanced System (Hbs™): A Novel Drug Delivery System for Oral Use, *Drug Dev. Ind Pharm.*, 10 (1984) 313.
- [36] Kawashima Y, Niwa T, Takeuchi H, Hino T & Itoh Y, Hollow microspheres for use as a floating controlled drug delivery system in the stomach, *J. Pharm. Sci.*, 81 (1992) 135.
- [37] Whitehead L, Fell JT & Collett JH, Development of a gastroretentive dosage form, *Eur. J. Pharm. Sci.*, 4 (1996) S 182.
- [38] Darandale SS & Vavia PR, Design of a gastroretentive mucoadhesive dosage form of furosemide for controlled release, *Acta Pharmaceutica Sinica B*, 2 (2012) 509. [39] Goole J, Hamdani J, Vanderbist F & Amighi K, In vitro and in vivo evaluation in healthy human volunteers of floating riboflavin minitabets, *J. Drug Del. Sci. Tech.*, 16 (2006) 351.
- [40] Ali J, Arora S, Ahuja A, Babbar AK, Sharma RK, Khar RK & Baboota S, Formulation and development of hydrodynamically balanced system for metformin: In vitro and in vivo evaluation, *European Journal of Pharmaceutics and Biopharmaceutics*, 67 (2007) 196.
- [41] Arza RAK, Gonugunta CSR & Veerareddy PR, Formulation and evaluation of swellable and floating gastroretentive Ciprofloxacin hydrochloride tablets, *AAPS Pharm Sci Tech*, 10 (2009) 220.
- [42] Fahmy RH, Statistical approach for assessing the influence of calcium silicate and HPMC on the Formulation of novel Alfuzosin hydrochloride mucoadhesive-floating beads as gastroretentive drug delivery systems, *AAPS Pharm Sci Tech*, 13 (2012) 990, DOI: 10.1208/s12249-012-9823-2.
- [43] Shakya R, Thapa P & Saha RN, In vitro and in vivo evaluation of gastroretentive floating drug delivery system of ofloxacin, *Asian Journal of Pharmaceutical sciences*, 8 (2013), 191.
- [44] Bomma R, Naidu RAS, Yamsani MR & Veerabrahma K, Development and evaluation of gastroretentive norfloxacin floating tablets, *Acta Pharm.*, 59 (2009) 211.
- [45] Prajapati S, Patel L & Patel C, Floating Matrix Tablets of Domperidone Formulation and Optimization Using Simplex Lattice Design, *Iranian Journal of Pharmaceutical Research*, 10 (2011) 447.
- [46] Yellanki SK, Singh J, Syed JA, Bigala R, Goranti S, Nerella KN, Design and Characterization of Amoxicillin Trihydrate Mucoadhesive Microspheres for Prolonged Gastric Retention, *International Journal of Pharmaceutical Sciences and Drug Research*, 2 (2010) 112.
- [47] Meka L, Kesavan B, Chinnala KM, Vobalaboina V & Yamsani MR, Preparation of a Matrix Type Multiple-Unit Gastro Retentive Floating Drug Delivery System for Captopril Based on Gas Formation Technique: In Vitro Evaluation, *AAPS Pharm Sci Tech*, 9 (2008) 612, DOI: 10.1208/s12249-008-9090-4.
- [48] Kumar MK, Shah MH, Ketkar A, Madhik KR & Paradkar A, Effect of drug solubility and different excipients on floating behaviour and release from glyceryl monooleate matrices, *Int J Pharm*, 272 (2004) 151.
- [49] Dave BS, Amin AF & Patel MM, Gastroretentive drug delivery system of Ranitidine Hydrochloride: Formulation and In Vitro Evaluation, *AAPS Pharm Sci Tech*, 5 (2004) 1.
- [50] Rapolu K, Sanka K, Vemula PK, Aatipamula V, MOHD AB & Diwan PV, Optimization and characterization of gastroretentive floating drug delivery system using Box-Behnken design, *Drug Dev Ind Pharm.*, 39 (2013) 1928, doi: 10.3109/03639045.2012.699068.
- [51] Khan AD & Bajpal M, Floating Drug Delivery System: An Overview, *Int. J. Pharm Tech Res.*, 2 (2010) 2497.
- [52] Nagigoti J & Shayed, Floating Drug Delivery System, *Int. J. Pharm.Sci. Nano.*, 2 (2009) 595.



***Corresponding Author:**

M Sharath Chandra Goud*

Email: goudsharathchandra@gmail.com